Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies

Summary The Glasgow prognostic score (GPS) and CAR‐HEMATOTOX (CAR‐HT) score identify multiple myeloma (MM) patients at high risk for immune‐mediated toxicity and early mortality with cellular immunotherapy. However, their association with outcomes in patients receiving T‐cell redirecting bispecific...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2024-11, Vol.205 (5), p.1830-1834
Hauptverfasser:	Akhtar, Othman Salim, Szabo, Aniko, Bhatlapenumarthi, Vineel, Forsberg, Mark, Balev, Metodi, Patwari, Anannya, Cheruvalath, Heloise, Bhutani, Divaya, Thanendrarajan, Sharmilan, Dhakal, Binod, Zangari, Maurizio, Patel, Tanvi, Shrestha, Asis, Al‐Hadidi, Samer, Cooper, Dennis, Lentzsch, Suzanne, Rhee, Frits, Shah, Mansi R., Bag, Aishee, D'Souza, Anita, Schinke, Carolina, Chakraborty, Rajshekhar, Shah, Nishi, Mohan, Meera
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Bispecific - therapeutic use Bispecific antibodies CAR‐HEMATOTOX Female Glasgow prognostic score Humans Immunotherapy Infections - etiology Infections - mortality Male Middle Aged Mortality Multiple myeloma Multiple Myeloma - immunology Multiple Myeloma - mortality Multiple Myeloma - therapy predictors Prognosis Recurrence Retrospective Studies Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!